Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neurosense Therapeutics Ltd

0.9963
+0.02092.14%
Volume:103.36K
Turnover:102.20K
Market Cap:23.90M
PE:-1.82
High:1.02
Open:1.02
Low:0.9600
Close:0.9754
Loading ...

Company Profile

Company Name:
Neurosense Therapeutics Ltd
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
17
Office Location:
Building B,11 HaMenofim Street,Herzliya,Israel
Zip Code:
4672562
Fax:
- -
Introduction:
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Directors

Name
Position
Alon Ben Noon
Chief Executive Officer, Director
Cary Claiborne
External Director
Christine Pellizzari
External Director
Mark Leuchtenberger
Chair of the Board
Caren Deardorf
Director
Yael German
Director

Shareholders

Name
Position
Alon Ben Noon
Chief Executive Officer, Director
Or Eisenberg
Chief Financial Officer
Ferenc Tracik
Chief Medical Officer